Table 1 Summary of the clinical characteristics of the discovery cohort
From: Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
Characteristics | No. (%) |
|---|---|
No. of patients | 662 |
Median age, years (range) | 64 (55–71) |
Gender | |
 Female | 278 (42) |
 Male | 384 (58) |
Cancer type | |
 Bladder cancer | 27 (4) |
 Esophagogastric cancer | 40 (6) |
 Head and neck cancer | 12 (2) |
 Melanoma | 287 (43) |
 Non-small cell lung cancer | 296 (45) |
Drug type | |
 Monotherapy | 608 (92) |
 Combination therapy | 54 (8) |
Treatment best response | |
 CR | 43 (6) |
 PD | 319 (48) |
 PR | 139 (21) |
 SD | 161 (24) |
Durable clinical benefit | |
 Benefit | 262 (40) |
 Nonbenefit | 400 (60) |
NOTCH4 status | |
 Wildtype | 599 (90) |
 Mutant | 63 (10) |